Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Thursday, January 8, 2009

The phase 1/phase 2 biotransformation enzymes

body odor
Note: This is the author's interpretation of the article referenced below, and therefore, may not be wholly accurate

In our quest to understand bloodborne odor problems as best we can, this is another post about the xenobiotic metabolizing enzymes, also known as the drug metabolizing enzymes or biotransformation enzymes. This is the group of enzymes largely responsible for dealing with external foreign compounds, and altering them into something the body knows what to do with - in the case of toxins, turning them into water soluble non-toxic compounds. These enzymes also catalyze metabolic processes with internal compounds. They deal with compounds of similar structures.

At the moment, these seem like a natural parameter for looking for a 'metabolic' culprit(s) in fecal body odor and other 'non-specific' metabolic body odors. Other enzymes seem to be quite specific for certain substrates, and perhaps a sufferer will have a certain smell only, such as 'sweaty feet syndrome' with isovaleric acidemia. But at the moment this is speculation. We don't want to rule anything out, but this group of cell enzymes seem the first point of enquiry.

Xenobiotic enzymes are mostly situated in the liver cells, but are also present in cells anywhere the body, as the evolutionary process over the generations has deemed sensible. (e.g. the small intestine. Grapefruit juice can greatly inhibit CYP3A4 activity in the small intestine, but seemingly not the CYP3A4 in the liver). Phase1 seems to be enzymes that catelyses oxidation, reduction or hydrolyze reactions. Phase2 enzymes are known as 'conjugating enzymes'; they add a molecule to a compound to make it neutral and water soluble. For instance, in sulfation, a sulfur molecule is added.

The phase1/phase2 approach may not be commonly used, yet possibly still taught to medical students. Currently FMO3 is likely not given as much importance compared to CYP450 as is noted in the article, Flavin mono-oxygenase (FMO)--the 'other' oxidase, by an FMO3 expert (Mitchell SC in London). Some may see their point, since most with TMAU seem to be 'fine' apart from the smell. But other health problems may turn out to be associated. Such as chronic fatigue, or aggravation to other medical conditions such as neurological conditions (learning disabilities, anxiety, epilepsy, fibromyalgia, auto-immune diseases, etc.) . Only time will tell.

Medical students are likely taught that any 'deficiency' in a xenobiotic metabolizing enzyme is likely to do with a phase 1 enzyme, and that phase 2 are rarely deficient, but 5% (or more) of the population are estimated to have a weak 'glucuronidation' enzyme. This is regarded as usually 'benign' but testimonies on the problem seem to indicate differently. Often the sufferer will easily develop jaundiced, since this enzyme is greatly responsible for detoxing bilirubin. It's known as Gilberts Syndrome.

Hopefully the CYP450 article below will add to understanding these enzymes.

http://www.anaesthetist.com/physiol/basics/metabol/cyp/Findex.htm#cyp.htm

0 comments:

Post a Comment